{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:45:06Z","timestamp":1789029906959,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The HIV epidemic has caused a dramatic increase in tuberculosis (TB) in East and southern Africa. Several strategies have the potential to reduce the burden of TB in high HIV prevalence settings, and cost and cost-effectiveness analyses can help to prioritize them when budget constraints exist. However, published cost and cost-effectiveness studies are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Our objective was to compare the cost, affordability and cost-effectiveness of seven strategies for reducing the burden of TB in countries with high HIV prevalence. A compartmental difference equation model of TB and HIV and recent cost data were used to assess the costs (year 2003 US$ prices) and effects (TB cases averted, deaths averted, DALYs gained) of these strategies in Kenya during the period 2004\u20132023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The three lowest cost and most cost-effective strategies were improving TB cure rates, improving TB case detection rates, and improving both together. The incremental cost of combined improvements to case detection and cure was below US$15 million per year (7.5% of year 2000 government health expenditure); the mean cost per DALY gained of these three strategies ranged from US$18 to US$34. Antiretroviral therapy (ART) had the highest incremental costs, which by 2007 could be as large as total government health expenditures in year 2000. ART could also gain more DALYs than the other strategies, at a cost per DALY gained of around US$260 to US$530. Both the costs and effects of treatment for latent tuberculosis infection (TLTI) for HIV+ individuals were low; the cost per DALY gained ranged from about US$85 to US$370. Averting one HIV infection for less than US$250 would be as cost-effective as improving TB case detection and cure rates to WHO target levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>To reduce the burden of TB in high HIV prevalence settings, the immediate goal should be to increase TB case detection rates and, to the extent possible, improve TB cure rates, preferably in combination. Realising the full potential of ART will require substantial new funding and strengthening of health system capacity so that increased funding can be used effectively.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-2458-5-130","type":"journal-article","created":{"date-parts":[[2005,12,13]],"date-time":"2005-12-13T07:27:15Z","timestamp":1134458835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence"],"prefix":"10.1186","volume":"5","author":[{"given":"Christine SM","family":"Currie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Floyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,12,12]]},"reference":[{"key":"285_CR1","volume-title":"Global Tuberculosis Control: Surveillance, Planning, Financing","author":"WHO","year":"2005","unstructured":"WHO: Global Tuberculosis Control: Surveillance, Planning, Financing. 2005, WHO\/HTM\/TB\/2005.349. Geneva"},{"key":"285_CR2","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1001\/archinte.163.9.1009","volume":"163","author":"EL Corbett","year":"2003","unstructured":"Corbett EL, Watt CJ, Walker N, Maher D, Williams GB, Raviglione MC, Dye C: The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine. 2003, 163: 1009-1021. 10.1001\/archinte.163.9.1009.","journal-title":"Archives of Internal Medicine"},{"key":"285_CR3","first-page":"1","volume-title":"WHO\/CDS\/TB\/2002","author":"WHO","year":"2002","unstructured":"WHO: An expanded DOTS framework for effective tuberculosis control. WHO\/CDS\/TB\/2002. Edited by: WHO. 2002, WHO: Geneva, 297: 1-20."},{"key":"285_CR4","first-page":"437","volume":"80","author":"C Dye","year":"2002","unstructured":"Dye C, Watt CJ, Bleed D: Low access to a highly effective therapy: a challenge for international tuberculosis control. Bulletin of the World Health Organization. 2002, 80: 437-444.","journal-title":"Bulletin of the World Health Organization"},{"key":"285_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0140-6736(04)16590-2","volume":"364","author":"J Pablo Gutierrez","year":"2004","unstructured":"Pablo Gutierrez J, Johns B, Adam T, Bertozzi SM, Tan-Torres Edejer T, Greener R, Hankins C, Evans DB: Achieving the WHO\/UNAIDS antiretroviral treatment 3 by 5 goal: what will it cost?. The Lancet. 2004, 364: 63-64. 10.1016\/S0140-6736(04)16590-2.","journal-title":"The Lancet"},{"key":"285_CR6","volume-title":"World Health Organization","author":"H Getahun","year":"2004","unstructured":"Getahun H, van Gorkom J, Harries A, Harrington M, Nunn P, Perriens J, Reid A, Vitoria M: Interim Policy on Collaborative TB\/HIV activities. World Health Organization. 2004, Geneva"},{"key":"285_CR7","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(02)08595-1","volume":"359","author":"A Creese","year":"2002","unstructured":"Creese A, Floyd K, Alban A, Guinness L: Cost-effectiveness of HIV\/AIDS interventions in Africa: a systematic review of the evidence. Lancet. 2002, 359: 1635-43. 10.1016\/S0140-6736(02)08595-1.","journal-title":"Lancet"},{"key":"285_CR8","first-page":"217","volume":"80","author":"MW Borgdorff","year":"2002","unstructured":"Borgdorff MW, Floyd K, Broekmans JF: Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. Bulletin of the World Health Organization. 2002, 80: 217-227.","journal-title":"Bulletin of the World Health Organization"},{"key":"285_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1472-9792(02)00077-X","volume":"83","author":"K Floyd","year":"2003","unstructured":"Floyd K: Costs and effectiveness \u2013 the impact of economic studies on TB control. Tuberculosis. 2003, 83: 187-200. 10.1016\/S1472-9792(02)00077-X.","journal-title":"Tuberculosis"},{"key":"285_CR10","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1097\/00002030-200311210-00013","volume":"17","author":"CSM Currie","year":"2003","unstructured":"Currie CSM, Williams BG, Cheng RC, Dye C: Tuberculosis epidemics driven by HIV: is prevention better than cure?. AIDS. 2003, 17: 2501-2508. 10.1097\/00002030-200311210-00013. For supplementary material, see http:\/\/www.who.int\/gtb and http:\/\/www.AIDSonline.com","journal-title":"AIDS"},{"issue":"9 Suppl 1","key":"285_CR11","first-page":"S14","volume":"7","author":"B Nganda","year":"2003","unstructured":"Nganda B, Wang'ombe J, Floyd K, Kangangi J: Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Machakos District, Kenya. Int J Tuberc Lung Dis. 2003, 7 (9 Suppl 1): S14-20.","journal-title":"Int J Tuberc Lung Dis"},{"key":"285_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/bmj.324.7331.193","volume":"324","author":"D Morgan","year":"2002","unstructured":"Morgan D, Mahe C, Mayanja B, Whitworth JA: Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study. BMJ. 2002, 324: 193-6. 10.1136\/bmj.324.7331.193.","journal-title":"BMJ"},{"key":"285_CR13","first-page":"231","volume":"6","author":"M Badri","year":"2002","unstructured":"Badri M, Ehrlich R, Pulerwitz T, Wood R, Maartens G: Tuberculosis should not be considered an AIDS-defining illness in areas with a high tuberculosis prevalence. Int J Tuberc Lung Dis. 2002, 6: 231-237.","journal-title":"Int J Tuberc Lung Dis"},{"key":"285_CR14","volume-title":"Geneva","author":"WHO","year":"2003","unstructured":"WHO: Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach. Geneva. 2003"},{"key":"285_CR15","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1126\/science.1086845","volume":"301","author":"BG Williams","year":"2003","unstructured":"Williams BG, Dye C: Antiretroviral drugs for tuberculosis control in the era of HIV\/AIDS:. Science. 2003, 301: 1535-1537. 10.1126\/science.1086845.","journal-title":"Science"},{"key":"285_CR16","volume-title":"Health Studies Branch, Population Division, U.S. Bureau of the Census","author":"Anonymous","year":"2003","unstructured":"Anonymous: HIV\/AIDS Surveillance Data Base. Health Studies Branch, Population Division, U.S. Bureau of the Census. 2003, Washington, D.C. USA 20233-8860. US Census Bureau"},{"key":"285_CR17","volume-title":"National HIV Surveillance Results: 2003","author":"Anonymous","year":"2003","unstructured":"Anonymous: National HIV Surveillance Results: 2003. 2003, National AIDS\/STD Control Programme, Research, Monitoring and Evaluation Unit, Ministry of Health: Nairobi, Kenya"},{"key":"285_CR18","volume-title":"Kenya Demographic and Health Survey 2003: Preliminary Report","author":"Anonymous","year":"2004","unstructured":"Anonymous: Kenya Demographic and Health Survey 2003: Preliminary Report. 2004, Central Bureau of Statistics, Nairobi, Kenya; Ministry of Health, Nairobi, Kenya; Kenya Medical Research Institute, Nairobi, Kenya; Centre for Disease Control, Nairobi, Kenya; MEASURE DHS+, ORC Macro, Calverton, Maryland, USA: Nairobi"},{"key":"285_CR19","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1097\/00002030-199908200-00016","volume":"13","author":"JC Bell","year":"1999","unstructured":"Bell JC, Rose DN, Sacks HS: Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective. AIDS. 1999, 13: 1549-1556. 10.1097\/00002030-199908200-00016.","journal-title":"AIDS"},{"key":"285_CR20","volume-title":"Coverage of selected health services for HIV\/AIDS prevention and care in less developed countries in 2001","author":"WHO","year":"2001","unstructured":"WHO: Coverage of selected health services for HIV\/AIDS prevention and care in less developed countries in 2001. 2001, Geneva, [http:\/\/who.int\/hiv\/pub\/prev_care\/isbn9241590319.pdf]"},{"key":"285_CR21","volume-title":"Geneva","author":"WHO","year":"2004","unstructured":"WHO: Report of a \"Lessons learnt\" workshop on the six ProTEST Pilot projects in Malawi, South Africa and Zambia. Geneva. 2004"},{"key":"285_CR22","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1086\/431482","volume":"41","author":"C Akileswaran","year":"2005","unstructured":"Akileswaran C, Lurie ML, Flanigan TP, Mayer KH: Lessons learned from use of highly active antiretroviral therapy in Africa. CID. 2005, 41: 376-385. 10.1086\/431482.","journal-title":"CID"},{"key":"285_CR23","volume-title":"ISBN 92 4 156207 2","author":"WHO","year":"2002","unstructured":"WHO: World Health Report 2002: Reducing Risks, promoting healthy life. ISBN 92 4 156207 2. 2002, Geneva"},{"key":"285_CR24","doi-asserted-by":"crossref","unstructured":"Gold MR, Siegel JE, Russell LB, Weinstein MC, eds: Cost-effectiveness in health and medicine. 1996, Oxford University Press: New York","DOI":"10.1093\/oso\/9780195108248.001.0001"},{"key":"285_CR25","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.1996.03540140060028","volume":"276","author":"L Russell","year":"1996","unstructured":"Russell L, Gold MR, Siegel JE, Daniels N, Weinstein MC: The role of cost-effectiveness analysis in health and medicine. JAMA. 1996, 276: 1172-1177. 10.1001\/jama.276.14.1172.","journal-title":"JAMA"},{"key":"285_CR26","volume-title":"World Health Organization","author":"A Lopez","year":"2000","unstructured":"Lopez A, Saloman JA, Ahmad O, Murria CJM, Mafat D: Life Tables for 191 Countries for 2000: Data, methods, results. World Health Organization. 2000, Geneva"},{"key":"285_CR27","unstructured":"Murray CJL, Lopez AD, eds: The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. 1996, Harvard University Press Cambridge"},{"key":"285_CR28","first-page":"295","volume":"76","author":"JR Glynn","year":"1998","unstructured":"Glynn JR, Warndorff DK, Fine PEM, Munthali MM, Sichone W, Ponnighaus JM: Measurement and determinants of tuberculosis outcome in Karonga District, Malawi. Bulletin of the World Health Organization. 1998, 76: 295-305.","journal-title":"Bulletin of the World Health Organization"},{"key":"285_CR29","first-page":"9","volume":"98","author":"AM Elliott","year":"1995","unstructured":"Elliott AM, Halwiindi B, Hayes RJ, Luo N, Mwinga AG, Tembo G, Machiels L, Steenbergen G, Pobee JOM, Nunn PP, McAdam KPWJ: The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia. J Trop Med Hyg. 1995, 98: 9-21.","journal-title":"J Trop Med Hyg"},{"key":"285_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0035-9203(98)91036-7","volume":"92","author":"AD Harries","year":"1998","unstructured":"Harries AD, Nyangulu DS, Kang'ombe C, Ndalama D, Glynn JR, Banda H, Wirima JJ, Salaniponi FM, Liomba G, Maher D, Nunn P: Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba Hospital, Malawi. Trans R Soc Trop Med Hyg. 1998, 92: 343-7. 10.1016\/S0035-9203(98)91036-7.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"285_CR31","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0140-6736(98)06439-3","volume":"353","author":"MJ Wawer","year":"1999","unstructured":"Wawer MJ, Sewankambo NK, Serwadda D, Quinn TC, Paxton LA, Kiwanuka N, Wabwire-Mangen F, Li C, Lutalo T, Nalugoda F, Gaydos CA, Moulton LH, Meehan MO, Ahmed S, Gray RH: Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet. 1999, 353: 525-35. 10.1016\/S0140-6736(98)06439-3.","journal-title":"Lancet"},{"key":"285_CR32","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/S0140-6736(95)91380-7","volume":"346","author":"HF Grosskurth","year":"1995","unstructured":"Grosskurth HF, Mosha J, Todd E, Mwijarubi A, Klokke K, Sonkoro P, Mayaud J, Changalucha , Nicoll A, ka Gina G: Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995, 346: 530-536. 10.1016\/S0140-6736(95)91380-7.","journal-title":"Lancet"},{"key":"285_CR33","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(00)04331-2","volume":"357","author":"RH Gray","year":"2001","unstructured":"Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, Lutalo T, Li X, vanCott T, Quinn TC: Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001, 357: 1149-53. 10.1016\/S0140-6736(00)04331-2.","journal-title":"Lancet"},{"key":"285_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00002030-200401020-00010","volume":"18","author":"TC Porco","year":"2004","unstructured":"Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, Grant RM, Osmond DH: Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS. 2004, 18: 81-8. 10.1097\/00002030-200401020-00010.","journal-title":"AIDS"},{"key":"285_CR35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S0140-6736(04)16607-5","volume":"364","author":"H Gayle","year":"2004","unstructured":"Gayle H, Lange JM: Seizing the opportunity to capitalise on the growing access to HIV treatment to expand HIV prevention. The Lancet. 2004, 364: 6-8. 10.1016\/S0140-6736(04)16607-5.","journal-title":"The Lancet"},{"key":"285_CR36","volume-title":"Report of the WHO\/UNAIDS International Consensus Meeting on Technical and Operational Recommendations for Emergency Scaling-up of Antiretroviral Therapy in Resource-Limited settings 18\u201321 November 2003","author":"UNAIDS\/WHO","year":"2003","unstructured":"UNAIDS\/WHO: Emergency scale-up of antiretroviral therapy in resource-limited settings: technical and operational recommendations to achieve 3 by 5. Report of the WHO\/UNAIDS International Consensus Meeting on Technical and Operational Recommendations for Emergency Scaling-up of Antiretroviral Therapy in Resource-Limited settings 18\u201321 November 2003. 2003, WHO: Geneva"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-5-130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2458-5-130\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-5-130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-5-130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T18:09:54Z","timestamp":1706810994000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/1471-2458-5-130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["285"],"URL":"https:\/\/doi.org\/10.1186\/1471-2458-5-130","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]},"assertion":[{"value":"7 April 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"130"}}